Cargando…

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting

BACKGROUND: Heart failure (HF) has a dramatic impact on worldwide health care systems that is determined by the growing prevalence of and the high exposure to cardiovascular and noncardiovascular events. Prognosis remains poor. We sought to compare a large population with HF across the ejection frac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stolfo, Davide, Lund, Lars H., Benson, Lina, Hage, Camilla, Sinagra, Gianfranco, Dahlström, Ulf, Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750084/ https://www.ncbi.nlm.nih.gov/pubmed/36326055 http://dx.doi.org/10.1161/JAHA.122.026708

Ejemplares similares

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2019)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries
por: Batra, Gorav, et al.
Publicado: (2022)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
por: Shahim, Angiza, et al.
Publicado: (2023)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Dilated Cardiomyopathy With Mid‐Range Ejection Fraction at Diagnosis: Characterization and Natural History
por: Gentile, Piero, et al.
Publicado: (2019)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study
por: Shahim, Angiza, et al.
Publicado: (2021)

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
por: Kapelios, Chris J, et al.
Publicado: (2023)

Impact of adherence to guideline‐directed therapy on risk of death in HF patients across an ejection fraction spectrum
por: Chen, Xiaojing, et al.
Publicado: (2023)

Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences
por: Castrichini, Matteo, et al.
Publicado: (2020)

Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis
por: Savarese, Gianluigi, et al.
Publicado: (2020)

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
por: Janse, Roemer J., et al.
Publicado: (2022)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure
por: Lindberg, Felix, et al.
Publicado: (2022)

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Discovering Distinct Phenotypical Clusters in Heart Failure Across the Ejection Fraction Spectrum: a Systematic Review
por: Meijs, Claartje, et al.
Publicado: (2023)

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
por: Fu, Michael, et al.
Publicado: (2022)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients
por: Raafs, Anne G., et al.
Publicado: (2022)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Persistent Recovery of Normal Left Ventricular Function and Dimension in Idiopathic Dilated Cardiomyopathy During Long‐Term Follow‐up: Does Real Healing Exist?
por: Merlo, Marco, et al.
Publicado: (2015)

Circulating neuregulin1‐β in heart failure with preserved and reduced left ventricular ejection fraction
por: Hage, Camilla, et al.
Publicado: (2020)

T1 mapping across the ejection fraction spectrum
por: Alaour, Bashir, et al.
Publicado: (2016)

Trends in cause‐specific readmissions in heart failure with preserved vs. reduced and mid‐range ejection fraction
por: Cui, Xiaotong, et al.
Publicado: (2020)

A very rare cause of pre‐capillary pulmonary hypertension: The PAMI syndrome
por: Iseppi, Manuela, et al.
Publicado: (2023)

Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v7mk3qv6fqiaqbs7gadth3ipr2